Roche/AbbVie's Venclexta Expanding Indications, One of Many Positive Catalysts at Wide-Moat Roche
Roche and AbbVie announced that they have filed for U.S. Food and Drug Administration approval of Venclexta in first-line acute myeloid leukemia, or AML, one of many recent positive announcements from wide-moat-rated Roche, which continues to look significantly undervalued at our slightly increased fair value estimate of CHF 337/$42 per share. The filing was based on data from two midstage studies, including the M14-358 study presented at the annual American Society of Clinical Oncology conferen...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.